ProKidney spikes after mid-stage trial data for lead asset

3 hours ago 1
CKD chronic kidney disease, text words typography written with wooden letter, health and medical

airdone

Shares of ProKidney (NASDAQ:PROK) climbed ~56% in the premarket on Tuesday after the cell therapy developer announced positive topline results from a mid-stage trial for its lead candidate, rilparencel, in patients with chronic kidney disease and diabetes.

Citing its Phase

Recommended For You

More Trending News

Read Entire Article